illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. hospital & health care
  6. ›
  7. Vetoquinol Global
Company logo

Vetoquinol Global | Sustainability Performance

https://www.vetoquinol.com/en
Linkedin

Develops, manufactures, and markets veterinary medicines and animal health products. Provides pharmaceuticals and nutritional supplements for livestock and companion animals.

1933

France

1,001 - 5,000 employees

Pharmaceuticals

$500M - 1B in revenue

$25M - 100M in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#6948
Overall
#389
in France
#162
in Pharmaceuticals

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Beyond Top 100

Overview
Governance
TargetsESG scores and exclusionsB-corp & CDP
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Nemera

France, Hospital & Health Care, Medical Device


Company logo
Bastide Le Confort Medical

France, Hospital & Health Care, Medical Device


Company logo
LNA Sante

France, Hospital & Health Care, Hospital & Health Care

Market cap

810.7M $, 2026▼7.2% YoY

Revenue

592.5M $, 2025▼2.7% YoY

R&D intensity

7.81% 2025

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

810.7M $, 2026▼7.2% YoY

Revenue

592.5M $, FY2025▼2.7% YoY

EBITDA

82.4M $, FY2025▼9.1% YoY

Operating margin

14% Industry: -24▼2.9% YoY

Revenue & EBITDA

$592.5MFY2025 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

76.9M 2024▼3.3% YoY

Capex

19.2M 2024▼11.8% YoY

Debt/equity ratio

0.0 Industry: 0▼NaN% YoY

R&D intensity

7.8%FY2025

R&D as % of revenue

R&D as % of revenue
Industry benchmark

Powered by illuminem

Return on invested capital

9.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

0.6

▼ 2.5%

2023

0.6

▲ 0.2%

2024

0.6

▼ 0.1%

2025

0.6

2028

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Not available

40%
Independent Directors

4 out of 10 incl. management

Powered by illuminem

Overall score

0

Environment

0

Social

0

Governance

0

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

CDP Scores


Climate Score

Not disclosed

Water Score

Not disclosed

A

A-

B

B-

C

C-

D

D-

Powered by illuminem and GIST impact

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees


Total sustainability employees

1


    Available in
    Scale package

    Access
  • Email

  • Email